Drug resistant falciparum malaria and the use of artesunate-based combinations: focus on clinical trials sponsored by TDR.
J Vector Borne Dis
;
2003 Sep-Dec; 40(3-4): 65-72
Artigo
em Inglês
| IMSEAR
| ID: sea-118033
ABSTRACT
Antimalarial drug resistance has now become a serious global challenge and is the principal reason for the decline in antimalarial drug efficacy. Malaria endemic countries need inexpensive and efficacious drugs. Preserving the life spans of antimalarial drugs is a key part of the strategy for rolling back malaria. Artemisinin-based combinations offer a new and potentially highly effective way to counter drug resistance. Clinical trials conducted in African children have attested to the good tolerability of oral artesunate when combined with standard antimalarial drugs. The cure rates of the different combinations were generally dependent on the degree of resistance to the companion drug. They were high for amodiaquine-artesunate, variable for sulfadoxine/pyrimethamine-artesunate, and poor for chloroquine-artesunate.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Assunto principal:
Plasmodium falciparum
/
Pirimetamina
/
Sesquiterpenos
/
Sulfadoxina
/
Organização Mundial da Saúde
/
Humanos
/
Resistência a Medicamentos
/
Ensaios Clínicos Controlados Aleatórios como Assunto
/
Cloroquina
/
Malária Falciparum
Tipo de estudo:
Ensaio Clínico Controlado
País/Região como assunto:
África
Idioma:
Inglês
Revista:
J Vector Borne Dis
Assunto da revista:
Parasitology
/
Tropical Medicine
Ano de publicação:
2003
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS